Détail du document
Identifiant

oai:pubmedcentral.nih.gov:1031...

Sujet
Short Report
Auteur
Miraclin, Angel T Mani, Arun Mathai Sivadasan, Ajith Nair, Aditya Christina, Munagapati Gojer, Abigail Ruth Milton, Sharon Jude Prakash, John A Benjamin, Rohit N Prabhakar, Appaswamy Thirumal Mathew, Vivek Aaron, Sanjith
Langue
en
Editeur

BMJ Publishing Group

Catégorie

BMJ Neurology Open

Année

2023

Date de référencement

05/09/2023

Mots clés
neuronal detectable antibodies patient teratoma
Métrique

Résumé

BACKGROUND: Opsoclonus–myoclonus–ataxia syndrome (OMAS) is characterised by the combination of opsoclonus and arrhythmic action myoclonus with axial ataxia and dysarthria.

In adults, a majority are paraneoplastic secondary to solid organ tumours and could harbour antibodies against intracellular epitopes; however, certain proportions have detectable antibodies to various neuronal cell surface antigens.

Anti-N-methyl-D-aspartate (NMDAR) antibodies and ovarian teratomas have been implicated in OMAS.

METHODS: Report of two cases and review of literature.

RESULTS: Two middle-aged women presented with subacute-onset, rapidly progressive OMAS and behavioural changes consistent with psychosis.

The first patient had detectable antibodies to NMDAR in the cerebrospinal fluid (CSF) alone.

Evaluation for ovarian teratoma was negative.

The second patient had no detectable antibodies in serum or CSF; however, she had an underlying ovarian teratoma.

Patient A was treated with pulse steroids, therapeutic plasma exchange (TPE) followed by bortezomib (BOR) and dexamethasone, while patient B was treated with steroids, TPE followed by surgical resection of ovarian teratoma.

Both patients had favourable outcomes and were asymptomatic at the 6 monthly follow-up.

CONCLUSIONS: With coexistent neuropsychiatric manifestations, OMAS can be considered a distinct entity of autoimmune encephalitis, pathogenesis being immune activation against known/unknown neuronal cell surface antigens.

The observation of absence of anti-NMDAR antibody in patients with teratoma-associated OMAS and vice versa is intriguing.

Further research on the potential role of ovarian teratoma in evoking neuronal autoimmunity and its targets is required.

The management challenge in both cases including the potential use of BOR has been highlighted.

Miraclin, Angel T,Mani, Arun Mathai,Sivadasan, Ajith,Nair, Aditya,Christina, Munagapati,Gojer, Abigail Ruth,Milton, Sharon,Jude Prakash, John A,Benjamin, Rohit N,Prabhakar, Appaswamy Thirumal,Mathew, Vivek,Aaron, Sanjith, 2023, Opsoclonus myoclonus ataxia syndrome, ovarian teratoma and anti-NMDAR antibody: an ‘unresolved’ mystery, BMJ Publishing Group

Partager

Source

Articles recommandés par ES/IODE IA

Computational modeling of metabolic reprogramming in rheumatoid arthritis synovial fibroblasts and cancer- associated fibroblasts;Modélisation computationnelle de la reprogrammation métabolique des fibroblastes synoviaux de polyarthrite rhumatoïde et fibroblastes associés au cancer
maladies associated modélisation métaboliques leurs disease regulatory biological synovial modeling cancer fibroblastes fibroblasts reprogramming métabolique reprogrammation régulation hif-1 rheumatoid arthritis rhumatoïde polyarthrite metabolic rasfs